NeuBase Therapeutics Price to Free Cash Flow Ratio 2010-2023 | NBSE

NeuBase Therapeutics price to free cash flow ratio from 2010 to 2023. Price to free cash flow ratio can be defined as

NeuBase Therapeutics Price to Free Cash Flow Ratio 2010-2023 | NBSE

NeuBase Therapeutics price to free cash flow ratio from 2010 to 2023. Price to free cash flow ratio can be defined as
Related Stocks
Company NameMarket
Cap
Amgen (AMGN)$155.8B
Bristol Myers Squibb (BMY)$118.1B
Vertex Pharmaceuticals (VRTX)$116B
Gilead Sciences (GILD)$111.9B
CSL (CSLLY)$86.5B
Regeneron Pharmaceuticals (REGN)$81.8B
GSK (GSK)$69.8B
Argenex SE (ARGX)$35.7B
Alnylam Pharmaceuticals (ALNY)$31.8B
BioNTech SE (BNTX)$25.9B
Biogen (BIIB)$23B
Illumina (ILMN)$21.7B
BeiGene (BGNE)$18.9B
Moderna (MRNA)$14.7B
Incyte (INCY)$13.6B
Genmab (GMAB)$13.5B
Insmed (INSM)$13.2B
BioMarin Pharmaceutical (BMRN)$12.1B
Bio-Techne Corp (TECH)$11.3B
Vaxcyte (PCVX)$11B
Sarepta Therapeutics (SRPT)$10.6B
Exelixis (EXEL)$9.9B
Exact Sciences (EXAS)$9.8B
QIAGEN (QGEN)$9.7B
Revolution Medicines (RVMD)$9.6B
Bio-Rad Laboratories (BIO.B)$9.4B
Intra-Cellular Therapies (ITCI)$9.1B
Roivant Sciences (ROIV)$8.7B
Repligen (RGEN)$7.9B
Ascendis Pharma (ASND)$7.4B